| DNA repair by ERCC1 in non–small-cell lung cancer and cisplatin-based adjuvant chemotherapy KA Olaussen, A Dunant, P Fouret, E Brambilla, F André, V Haddad, ... New England Journal of Medicine 355 (10), 983-991, 2006 | 2367 | 2006 |
| ERCC1 isoform expression and DNA repair in non–small-cell lung cancer L Friboulet, KA Olaussen, JP Pignon, FA Shepherd, MS Tsao, S Graziano, ... New England Journal of Medicine 368 (12), 1101-1110, 2013 | 444 | 2013 |
| Making the first move in EGFR-driven or ALK-driven NSCLC: first-generation or next-generation TKI? G Recondo, F Facchinetti, KA Olaussen, B Besse, L Friboulet Nature reviews Clinical oncology 15 (11), 694-708, 2018 | 335 | 2018 |
| Cyclooxygenase-2 as a target for anticancer drug development JB Méric, S Rottey, K Olaussen, JC Soria, D Khayat, O Rixe, JP Spano Critical reviews in oncology/hematology 59 (1), 51-64, 2006 | 285 | 2006 |
| Tumor mutation burden as a biomarker in resected non–small-cell lung cancer S Devarakonda, F Rotolo, MS Tsao, I Lanc, E Brambilla, A Masood, ... Journal of Clinical Oncology 36 (30), 2995-3006, 2018 | 247 | 2018 |
| Cisplatin resistance associated with PARP hyperactivation J Michels, I Vitale, L Galluzzi, J Adam, KA Olaussen, O Kepp, L Senovilla, ... Cancer research 73 (7), 2271-2280, 2013 | 190 | 2013 |
| Diverse resistance mechanisms to the third-generation ALK inhibitor lorlatinib in ALK-rearranged lung cancer G Recondo, L Mezquita, F Facchinetti, D Planchard, A Gazzah, L Bigot, ... Clinical Cancer Research 26 (1), 242-255, 2020 | 161 | 2020 |
| A novel epidermal growth factor receptor inhibitor promotes apoptosis in non–small cell lung cancer cells resistant to erlotinib T de La Motte Rouge, L Galluzzi, KA Olaussen, Y Zermati, E Tasdemir, ... Cancer research 67 (13), 6253-6262, 2007 | 155 | 2007 |
| Predictors of chemotherapy efficacy in non-small-cell lung cancer: a challenging landscape KA Olaussen, S Postel-Vinay Annals of Oncology 27 (11), 2004-2016, 2016 | 152 | 2016 |
| Telomeres and telomerase as targets for anticancer drug development KA Olaussen, K Dubrana, J Domont, JP Spano, L Sabatier, JC Soria Critical reviews in oncology/hematology 57 (3), 191-214, 2006 | 151 | 2006 |
| The potential of exploiting DNA-repair defects for optimizing lung cancer treatment S Postel-Vinay, E Vanhecke, KA Olaussen, CJ Lord, A Ashworth, JC Soria Nature reviews Clinical oncology 9 (3), 144-155, 2012 | 143 | 2012 |
| Prognostic impact of vitamin B6 metabolism in lung cancer L Galluzzi, I Vitale, L Senovilla, KA Olaussen, G Pinna, T Eisenberg, ... Cell reports 2 (2), 257-269, 2012 | 131 | 2012 |
| Telomere length, telomeric proteins and genomic instability during the multistep carcinogenic process CM Raynaud, L Sabatier, O Philipot, KA Olaussen, JC Soria Critical reviews in oncology/hematology 66 (2), 99-117, 2008 | 129 | 2008 |
| Facts and new hopes on selective FGFR inhibitors in solid tumors F Facchinetti, A Hollebecque, R Bahleda, Y Loriot, KA Olaussen, ... Clinical Cancer Research 26 (4), 764-774, 2020 | 119 | 2020 |
| MutS homologue 2 and the long-term benefit of adjuvant chemotherapy in lung cancer International Adjuvant Lung Trial-Bio investigators, NS Kamal, JC Soria, ... Clinical cancer research 16 (4), 1206-1215, 2010 | 119 | 2010 |
| ERCC1 and RRM1: ready for prime time? B Besse, KA Olaussen, JC Soria Journal of Clinical Oncology 31 (8), 1050-1060, 2013 | 116 | 2013 |
| ERCC1 as a risk stratifier in platinum-based chemotherapy for nonsmall-cell lung cancer KA Olaussen, G Mountzios, JC Soria Current opinion in pulmonary medicine 13 (4), 284-289, 2007 | 116 | 2007 |
| A high-throughput screen identifies PARP1/2 inhibitors as a potential therapy for ERCC1-deficient non-small cell lung cancer S Postel-Vinay, I Bajrami, L Friboulet, R Elliott, Y Fontebasso, N Dorvault, ... Oncogene 32 (47), 5377-5387, 2013 | 103 | 2013 |
| Are RAS mutations predictive markers of resistance to standard chemotherapy? Y Loriot, P Mordant, E Deutsch, KA Olaussen, JC Soria Nature reviews Clinical oncology 6 (9), 528-534, 2009 | 103 | 2009 |
| Inhibition of Chk1 kills tetraploid tumor cells through a p53-dependent pathway I Vitale, L Galluzzi, S Vivet, L Nanty, P Dessen, L Senovilla, KA Olaussen, ... PloS one 2 (12), e1337, 2007 | 95 | 2007 |
